Company: ABUS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001447028-25-000126
Chunk: 23

Company: Arbutus Biopharma Corp
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 23
---
 2023169,867,414 $1,349,821 $81,270 $(1,276,652)$(48,421)$106,018 Stock-based compensation expense— — 2,014 — — 2,014 Issuance of common shares pursuant to the Open Market Sale Agreement8,666,077 21,765 — — — 21,765 Issuance of common shares pursuant to exercise of options1,126,691 4,268 (1,814)— — 2,454 Issuance of common shares pursuant to ESPP121,563 271 (60)— — 211 Issuance of common shares upon vesting of RSUs410,482 1,190 (1,190)— — — Unrealized gain on available-for-sale securities— — — — 50 50 Net loss— — — (17,875)— (17,875)Balance March 31, 2024180,192,227 $1,377,315 $80,220 $(1,294,527)$(48,371)$114,637 Stock-based compensation expense— — 3,180 — — 3,180 Issuance of common shares pursuant to the Open Market Sale Agreement7,833,922 22,359 — — — 22,359 Issuance of common shares pursuant to exercise of options712,895 3,660 (1,649)— — 2,011 Unrealized gain on available-for-sale securities— — — — 63 63 Net loss— — — (19,796)— (19,796)Balance June 30, 2024188,739,044 $1,403,334 $81,751 $(1,314,323)$(48,308)$122,454 Stock-based compensation expense— — 2,160 — — 2,160 Issuance of common shares pursuant to exercise of options593,321 3,996 (2,406)— — 1,590 Issuance of common shares pursuant to ESPP105,770 265 (80)— — 185 Unrealized gain on available-for-sale securities— —